Covered recipient · General Payments record
BRUCE A SALZBERG
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$87,088.72
183 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $54,225.00 | 16 |
| Travel and Lodging | $17,761.90 | 29 |
| Consulting Fee | $12,265.00 | 2 |
| Food and Beverage | $2,752.96 | 133 |
| Education | $83.86 | 3 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Scientific Affairs, LLC | $60,615.59 | 45 |
| Janssen Biotech, Inc. | $9,767.27 | 24 |
| Takeda Pharmaceuticals U.S.A., Inc. | $8,737.25 | 11 |
| PFIZER INC. | $7,243.84 | 29 |
| AbbVie, Inc. | $203.67 | 30 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $168.40 | 21 |
| Janssen Pharmaceuticals, Inc | $76.00 | 2 |
| Allergan Inc. | $67.80 | 9 |
| Celgene Corporation | $43.95 | 1 |
| Ferring Pharmaceuticals Inc. | $38.15 | 3 |
| UCB, Inc. | $31.40 | 2 |
| Gilead Sciences, Inc. | $25.02 | 1 |
| QOL Medical, LLC | $16.42 | 1 |
| Endo Pharmaceuticals Inc. | $16.26 | 1 |
| Ironwood Pharmaceuticals, Inc | $13.02 | 1 |
| Merck Sharp & Dohme Corporation | $12.42 | 1 |
| Daiichi Sankyo Inc. | $12.26 | 1 |
Page 1 of 4; records 1–50 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
BRUCE A SALZBERG
NPI 1376528943 · CMS profile ID 243136
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
SUWANEE, GA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 4; records 1–50 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1376528943?year=2019&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- BRUCE A SALZBERG, NPI 1376528943, CMS profile ID 243136. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 4; records 1–50 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1376528943?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). BRUCE A SALZBERG, NPI 1376528943, CMS profile ID 243136. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 4; records 1–50 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1376528943?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- BRUCE A SALZBERG, NPI 1376528943, CMS profile ID 243136, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 4; records 1–50 of 183 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1376528943?year=2019&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
183 matching records · $87,088.72 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–50 of 183.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.79 | 12/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684920703 | CMS |
| AbbVie, Inc. | $23.90 | 12/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648063571 | CMS |
| Ferring Pharmaceuticals Inc. | $12.18 | 12/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 655215529 | CMS |
| Gilead Sciences, Inc. | $25.02 | 12/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681597147 | CMS |
| Janssen Biotech, Inc. | $20.25 | 12/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658688771 | CMS |
| Celgene Corporation | $43.95 | 12/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672982279 | CMS |
| Janssen Biotech, Inc. | $4.64 | 12/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658688767 | CMS |
| PFIZER INC. | $14.14 | 12/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673698749 | CMS |
| PFIZER INC. | $20.63 | 12/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673777189 | CMS |
| PFIZER INC. | $148.03 | 11/26/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673832237 | CMS |
| PFIZER INC. | $131.79 | 11/26/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673833255 | CMS |
| PFIZER INC. | $426.36 | 11/26/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673836429 | CMS |
| Allergan Inc. | $2.91 | 11/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671078479 | CMS |
| Janssen Scientific Affairs, LLC | $2,575.00 | 11/20/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657606117 | CMS |
| Janssen Scientific Affairs, LLC | $4,025.00 | 11/20/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657606119 | CMS |
| Janssen Biotech, Inc. | $21.95 | 11/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658688763 | CMS |
| PFIZER INC. | $3.03 | 11/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673775859 | CMS |
| Janssen Biotech, Inc. | $18.00 | 11/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658688760 | CMS |
| Janssen Scientific Affairs, LLC | $2,282.90 | 11/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657606113 | CMS |
| Janssen Scientific Affairs, LLC | $112.62 | 11/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657606115 | CMS |
| PFIZER INC. | $14.17 | 11/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673836563 | CMS |
| Janssen Scientific Affairs, LLC | $77.40 | 11/15/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657606111 | CMS |
| PFIZER INC. | $253.55 | 11/13/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673829913 | CMS |
| PFIZER INC. | $303.10 | 11/13/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673830175 | CMS |
| Janssen Biotech, Inc. | $1.58 | 11/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658688756 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $3.34 | 11/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 684920699 | CMS |
| AbbVie, Inc. | $12.86 | 11/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648063567 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $84.10 | 11/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681872095 | CMS |
| Janssen Biotech, Inc. | $18.54 | 11/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658688753 | CMS |
| Janssen Scientific Affairs, LLC | $1,150.00 | 11/06/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657606099 | CMS |
| Janssen Scientific Affairs, LLC | $2,575.00 | 11/06/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657606101 | CMS |
| Janssen Scientific Affairs, LLC | $4,025.00 | 11/06/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657606103 | CMS |
| Janssen Scientific Affairs, LLC | $521.25 | 11/06/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657606105 | CMS |
| Janssen Scientific Affairs, LLC | $1,196.50 | 11/06/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657606107 | CMS |
| Janssen Scientific Affairs, LLC | $119.81 | 11/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657606109 | CMS |
| AbbVie, Inc. | $4.87 | 11/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648063569 | CMS |
| Janssen Biotech, Inc. | $4.10 | 10/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658688749 | CMS |
| Janssen Scientific Affairs, LLC | $124.58 | 10/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657606097 | CMS |
| AbbVie, Inc. | $22.27 | 10/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648063565 | CMS |
| Janssen Biotech, Inc. | $15.19 | 10/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658688737 | CMS |
| PFIZER INC. | $7.97 | 10/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673169027 | CMS |
| PFIZER INC. | $14.01 | 10/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673171361 | CMS |
| Janssen Pharmaceuticals, Inc | $38.00 | 10/17/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659259319 | CMS |
| Janssen Pharmaceuticals, Inc | $38.00 | 10/17/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659259321 | CMS |
| AbbVie, Inc. | $5.16 | 10/15/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 648063561 | CMS |
| Janssen Scientific Affairs, LLC | $4,025.00 | 10/11/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657606095 | CMS |
| Janssen Scientific Affairs, LLC | $42.97 | 10/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657606093 | CMS |
| Janssen Scientific Affairs, LLC | $28.86 | 10/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657606089 | CMS |
| Janssen Scientific Affairs, LLC | $30.62 | 10/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657606091 | CMS |
| Janssen Scientific Affairs, LLC | $859.37 | 10/04/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657606085 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2024 | Principal investigator | $35,777.10 | 3 |
| PY2023 | Principal investigator | $4,640.61 | 4 |
| PY2022 | Principal investigator | $52,325.70 | 12 |
| PY2021 | Principal investigator | $131,307.67 | 47 |
| PY2020 | Recipient | $7,898.24 | 3 |
| PY2020 | Principal investigator | $335,230.92 | 133 |
| PY2019 | Recipient | $12,040.75 | 4 |
| PY2019 | Principal investigator | $611,218.71 | 92 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
136 records in PY2020
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Allergan, Inc. | $951.68 | 12/31/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double- Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 721318565 |
| Principal investigator 1 | Allergan, Inc. | $1,905.00 | 12/31/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-Controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with moderately to Severely Active Croh | No dispute reported | 06/30/2026 | 721318659 |
| Principal investigator 1 | AbbVie Inc. | $1,312.28 | 12/30/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-234 | No dispute reported | 06/30/2026 | 721203825 |
| Principal investigator 1 | AbbVie Inc. | $10,292.40 | 12/30/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-533 | No dispute reported | 06/30/2026 | 721203847 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,353.00 | 12/23/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY ASSOCIATES | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis | No dispute reported | 06/30/2026 | 742088889 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,339.26 | 12/12/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719487673 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,921.55 | 12/12/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719487679 |
| Principal investigator 1 | AbbVie Inc. | $2,282.40 | 12/07/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-533 | No dispute reported | 06/30/2026 | 721200011 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,242.90 | 12/01/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VEDOLIZUMAB SUBCUTANEOUS AS MAINTENANCE THERAPY IN SUBJECTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO ACHIEVED CLINICAL RESPONSE FOLLOWING OPEN-LABEL VEDOLIZUMAB INTRAVENOUS THERAPY | No dispute reported | 06/30/2026 | 737093447 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16.86 | 11/30/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719487667 |
| Principal investigator 1 | Janssen Research & Development, LLC | $21.60 | 11/30/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719487669 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,426.00 | 11/19/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 719487599 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,363.00 | 11/18/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY ASSOCIATES | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease | No dispute reported | 06/30/2026 | 742088887 |
| Principal investigator 1 | AbbVie Inc. | $1,079.18 | 10/30/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-234 | No dispute reported | 06/30/2026 | 721193861 |
| Principal investigator 1 | AbbVie Inc. | $3,075.60 | 10/29/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-533 | No dispute reported | 06/30/2026 | 721193577 |
| Principal investigator 1 | Genentech, Inc. | $3,904.60 | 10/27/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | INDXN MAIN ETRO PBO | No dispute reported | 06/30/2026 | 857142267 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 10/27/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | A PHASE 3 LONG-TERM SAFETY EXTENSION STUDY OF SHP647 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (AIDA) | No dispute reported | 06/30/2026 | 737091175 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,970.00 | 10/26/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALIST S PC | A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 719485255 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,772.00 | 10/26/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALIST S PC | A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719485259 |
| Principal investigator 1 | PFIZER INC. | $35.94 | 10/22/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | A MULTICENTER OPENLABEL STUDY OF CP690550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 742929853 |
| Principal investigator 1 | PFIZER INC. | $682.81 | 10/22/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | A MULTICENTER OPENLABEL STUDY OF CP690550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 742929857 |
| Principal investigator 1 | AbbVie Inc. | $579.10 | 10/21/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | P11-282 | No dispute reported | 06/30/2026 | 721191637 |
| Principal investigator 1 | Gilead Sciences, Inc. | $135.00 | 10/21/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY ASSOCIATES | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease | No dispute reported | 06/30/2026 | 742088885 |
| Principal investigator 1 | Janssen Research & Development, LLC | $250.00 | 10/15/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALIST S PC | A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 719485251 |
| Principal investigator 1 | AbbVie Inc. | $3,220.80 | 09/30/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-675 | No dispute reported | 06/30/2026 | 721188551 |
| Principal investigator 1 | AbbVie Inc. | $57.60 | 09/30/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-533 | No dispute reported | 06/30/2026 | 721189281 |
| Principal investigator 1 | AbbVie Inc. | $1,290.86 | 09/28/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-234 | No dispute reported | 06/30/2026 | 721187163 |
| Principal investigator 1 | AbbVie Inc. | $502.50 | 09/28/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-430 | No dispute reported | 06/30/2026 | 721187255 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 09/25/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALIST S PC | A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719485247 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,671.00 | 09/23/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY ASSOCIATES | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis | No dispute reported | 06/30/2026 | 742088881 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,192.00 | 09/23/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY ASSOCIATES | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease | No dispute reported | 06/30/2026 | 742088883 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,000.00 | 09/22/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | EFFICACY AND SAFETY OF SHP647 AS MAINTENANCE TREATMENT IN PARTICIPANTS WITH MODERATE TO SEVERE CROHN?S DISEASE (CARMEN CD 307) | No dispute reported | 06/30/2026 | 737088773 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 09/22/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | EFFICACY AND SAFETY OF SHP647 AS MAINTENANCE TREATMENT IN PARTICIPANTS WITH MODERATE TO SEVERE CROHN?S DISEASE (CARMEN CD 307) | No dispute reported | 06/30/2026 | 737088775 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,055.00 | 09/22/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | A PHASE 4 OPEN-LABEL STUDY TO EVALUATE VEDOLIZUMAB IV DOSE OPTIMIZATION ON TREATMENT OUTCOMES IN NONRESPONDERS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (ENTERPRET) | No dispute reported | 06/30/2026 | 737088809 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $11,288.16 | 09/21/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, Pc | A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 736758907 |
| Principal investigator 1 | AbbVie Inc. | $1,484.40 | 09/09/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-533 | No dispute reported | 06/30/2026 | 721185537 |
| Principal investigator 1 | Allergan, Inc. | $700.00 | 09/03/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 721295111 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,131.30 | 09/01/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EFFICACY AND SAFETY STUDY OF SHP647 AS INDUCTION THERAPY IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS (FIGARO UC 302) | No dispute reported | 06/30/2026 | 737087385 |
| Principal investigator 1 | AbbVie Inc. | $37.80 | 08/31/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-234 | No dispute reported | 06/30/2026 | 721184251 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,462.00 | 08/24/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALIST S PC | A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719485243 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,162.00 | 08/24/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 719487591 |
| Principal investigator 1 | Gilead Sciences, Inc. | $3,885.00 | 08/19/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY ASSOCIATES | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease | No dispute reported | 06/30/2026 | 742088879 |
| Principal investigator 1 | AbbVie Inc. | $1,029.60 | 08/04/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-533 | No dispute reported | 06/30/2026 | 721179459 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,944.00 | 07/27/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 719487659 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,937.00 | 07/27/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 719487663 |
| Principal investigator 1 | AbbVie Inc. | $569.79 | 07/23/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | P11-282 | No dispute reported | 06/30/2026 | 721176595 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 07/23/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 721286489 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 07/23/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 721286545 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 07/23/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 721286609 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 07/23/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 721287143 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 07/21/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 721285743 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 07/14/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 721283505 |
| Principal investigator 1 | AbbVie Inc. | $1,196.36 | 07/06/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-234 | No dispute reported | 06/30/2026 | 721174923 |
| Principal investigator 1 | AbbVie Inc. | $195.00 | 07/01/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-430 | No dispute reported | 06/30/2026 | 721174241 |
| Principal investigator 1 | AbbVie Inc. | $100.00 | 06/30/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-431 | No dispute reported | 06/30/2026 | 721173803 |
| Recipient | UCB Biosciences Inc. | $7,800.00 | 06/22/2020 | Covered Recipient Physician | A Non-Interventional, Long term, Post-Marketing Registry of Patients Treated with Certolizumab Pegol CIMZIA For Crohn's Disease | No dispute reported | 06/30/2026 | 746122611 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,232.00 | 06/19/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALIST S PC | A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 719485239 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,353.00 | 06/17/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY ASSOCIATES | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis | No dispute reported | 06/30/2026 | 742088877 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,324.00 | 06/10/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 719487595 |
| Principal investigator 1 | Janssen Research & Development, LLC | $762.60 | 06/09/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719487611 |
| Principal investigator 1 | Janssen Research & Development, LLC | $252.70 | 06/09/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719487615 |
| Principal investigator 1 | Janssen Research & Development, LLC | $540.06 | 06/09/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719487619 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7.86 | 06/09/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719487623 |
| Principal investigator 1 | Janssen Research & Development, LLC | $36.26 | 06/09/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719487627 |
| Principal investigator 1 | Janssen Research & Development, LLC | $29.03 | 06/09/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719487631 |
| Principal investigator 1 | Janssen Research & Development, LLC | $34.74 | 06/09/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719487635 |
| Principal investigator 1 | Janssen Research & Development, LLC | $45.88 | 06/09/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719487639 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17.34 | 06/09/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719487643 |
| Principal investigator 1 | Janssen Research & Development, LLC | $49.48 | 06/09/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719487647 |
| Principal investigator 1 | Janssen Research & Development, LLC | $141.00 | 06/09/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719487649 |
| Principal investigator 1 | Janssen Research & Development, LLC | $373.60 | 06/09/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719487653 |
| Principal investigator 1 | PFIZER INC. | $1,717.14 | 06/04/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | A MULTICENTER OPENLABEL STUDY OF CP690550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 742941531 |
| Principal investigator 1 | AbbVie Inc. | $2,302.80 | 05/29/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-533 | No dispute reported | 06/30/2026 | 721168761 |
| Principal investigator 1 | AbbVie Inc. | $2,706.00 | 05/28/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-431 | No dispute reported | 06/30/2026 | 721168531 |
| Principal investigator 1 | AbbVie Inc. | $146.25 | 05/28/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-433 | No dispute reported | 06/30/2026 | 721168543 |
| Principal investigator 1 | AbbVie Inc. | $1,469.78 | 05/27/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-234 | No dispute reported | 06/30/2026 | 721167419 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,531.00 | 05/25/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALIST S PC | A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719485236 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,726.00 | 05/20/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY ASSOCIATES | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease | No dispute reported | 06/30/2026 | 742088875 |
| Principal investigator 1 | Genentech, Inc. | $2,425.50 | 05/14/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES | No dispute reported | 06/30/2026 | 857142261 |
| Principal investigator 1 | AbbVie Inc. | $5,498.00 | 04/30/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-675 | No dispute reported | 06/30/2026 | 721163699 |
| Principal investigator 1 | AbbVie Inc. | $2,891.20 | 04/30/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-533 | No dispute reported | 06/30/2026 | 721164081 |
| Principal investigator 1 | AbbVie Inc. | $10,267.75 | 04/30/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-431 | No dispute reported | 06/30/2026 | 721164371 |
| Principal investigator 1 | AbbVie Inc. | $3,244.46 | 04/27/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-234 | No dispute reported | 06/30/2026 | 721162329 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,498.00 | 04/27/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY ASSOCIATES | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease | No dispute reported | 06/30/2026 | 742088873 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,164.00 | 04/27/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALIST S PC | A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 719485231 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,697.00 | 04/17/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALIST S PC | A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719485227 |
| Principal investigator 1 | AbbVie Inc. | $1,274.48 | 03/31/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-234 | No dispute reported | 06/30/2026 | 721159439 |
| Principal investigator 1 | AbbVie Inc. | $927.60 | 03/30/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-675 | No dispute reported | 06/30/2026 | 721158293 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,500.00 | 03/27/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALIST S PC | A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 719485217 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 03/26/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 721267055 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 03/26/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 721267445 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $68.85 | 03/26/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Associates | Phase 2 UC | No dispute reported | 06/30/2026 | 736758905 |
| Principal investigator 1 | AbbVie Inc. | $2,594.77 | 03/25/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | P11-282 | No dispute reported | 06/30/2026 | 721156849 |
| Principal investigator 1 | Janssen Research & Development, LLC | $91.00 | 03/23/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALIST S PC | A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719485205 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,015.00 | 03/18/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY ASSOCIATES | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis | No dispute reported | 06/30/2026 | 742088867 |
| Principal investigator 1 | Gilead Sciences, Inc. | $5,968.00 | 03/18/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY ASSOCIATES | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease | No dispute reported | 06/30/2026 | 742088869 |
| Principal investigator 1 | Gilead Sciences, Inc. | $10,200.00 | 03/18/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY ASSOCIATES | Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 742088871 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 03/17/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 721264651 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,499.00 | 03/16/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists | Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 719487587 |
| Principal investigator 1 | PFIZER INC. | $31,332.00 | 03/12/2020 | Non-covered Recipient Entity Atlanta Gastro Specialists | A MULTICENTER OPENLABEL STUDY OF CP690550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 742953499 |
| Principal investigator 1 | AbbVie Inc. | $1,287.80 | 03/02/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-675 | No dispute reported | 06/30/2026 | 721154087 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,515.00 | 03/02/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALIST S PC | A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719485211 |
| Principal investigator 1 | AbbVie Inc. | $1,453.20 | 02/28/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-533 | No dispute reported | 06/30/2026 | 721153569 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,464.00 | 02/27/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALIST S PC | A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 719485223 |
| Recipient | Eli Lilly and Company | $28.24 | 02/26/2020 | Covered Recipient Physician | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | No dispute reported | 06/30/2026 | 728717625 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 02/25/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 721260287 |
| Principal investigator 1 | PFIZER INC. | $939.06 | 02/25/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | A MULTICENTER OPENLABEL STUDY OF CP690550 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 742953379 |
| Principal investigator 1 | AbbVie Inc. | $11,530.86 | 02/24/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-234 | No dispute reported | 06/30/2026 | 721151907 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,229.00 | 02/24/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY ASSOCIATES | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease | No dispute reported | 06/30/2026 | 742088863 |
| Principal investigator 1 | Gilead Sciences, Inc. | $14,400.00 | 02/24/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY ASSOCIATES | Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 742088865 |
| Principal investigator 1 | Genentech, Inc. | $1,080.90 | 02/05/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | AN OPEN LABEL EXTENSION AND SAFETY MONITORING STUDY OF MODERATE TO SEVERE ULCERATIVE COLITIS PATIENTS PREVIOUSLY ENROLLED IN ETROLIZUMAB PHASE II III STUDIES | No dispute reported | 06/30/2026 | 743032011 |
| Principal investigator 1 | AbbVie Inc. | $14,378.20 | 01/31/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-675 | No dispute reported | 06/30/2026 | 721148751 |
| Principal investigator 1 | AbbVie Inc. | $1,196.36 | 01/31/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-234 | No dispute reported | 06/30/2026 | 721148839 |
| Principal investigator 1 | AbbVie Inc. | $1,087.20 | 01/31/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-533 | No dispute reported | 06/30/2026 | 721148849 |
| Principal investigator 1 | Allergan, Inc. | $315.00 | 01/28/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 721250927 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 01/28/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 721252533 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 01/28/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 721252771 |
| Principal investigator 1 | Allergan, Inc. | $700.00 | 01/28/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 721253097 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 01/28/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 54-WEEK TREATMENT, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE- DUMMY, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL-GROUP PHASE 2 STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 721254075 |
| Recipient | Eli Lilly and Company | $70.00 | 01/28/2020 | Covered Recipient Physician | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | No dispute reported | 06/30/2026 | 728717553 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $750.00 | 01/28/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | ENTYVIO (VEDOLIZUMAB) LONG-TERM SAFETY STUDY: AN INTERNATIONAL OBSERVATIONAL PROSPECTIVE COHORT STUDY COMPARING VEDOLIZUMAB TO OTHER BIOLOGIC AGENTS IN PATIENTS WITH ULCERATIVE COLITIS OR CROHN'S DISEASE | No dispute reported | 06/30/2026 | 737068923 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,353.00 | 01/27/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY ASSOCIATES | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis | No dispute reported | 06/30/2026 | 742088859 |
| Principal investigator 1 | Gilead Sciences, Inc. | $16,144.00 | 01/27/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY ASSOCIATES | Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 742088861 |
| Principal investigator 1 | Janssen Research & Development, LLC | $19,464.00 | 01/27/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALIST S PC | A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients with Moderately to Severely Active Crohn's Disease | No dispute reported | 06/30/2026 | 719485215 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,465.00 | 01/27/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALIST S PC | A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to that of Adalimumab in the Treatment of Biologic Nave Subjects with Moderately-to-Severely Active Crohns Disease | No dispute reported | 06/30/2026 | 719485219 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,928.00 | 01/27/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 719487603 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,708.00 | 01/27/2020 | Non-covered Recipient Entity Atlanta Gastroenterology Specialists, PC | Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 719487607 |
| Principal investigator 1 | Allergan, Inc. | $315.00 | 01/14/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 721246049 |
| Principal investigator 1 | Allergan, Inc. | $315.00 | 01/14/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 721246069 |
| Principal investigator 1 | Allergan, Inc. | $700.00 | 01/14/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 721246305 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 01/14/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 721246525 |
| Principal investigator 1 | Allergan, Inc. | $315.00 | 01/14/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 721246939 |
| Principal investigator 1 | Allergan, Inc. | $86.00 | 01/14/2020 | Non-covered Recipient Entity COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP | A 52-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO AND ACTIVE- CONTROLLED, OPERATIONALLY SEAMLESS PHASE 2B/3, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRAZIKUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE | No dispute reported | 06/30/2026 | 721247001 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 01/14/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | STUDY OF THE EFFECT OF SHP647 AS MAINTENANCE TREATMENT IN PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS WHO ACHIEVED CLINICAL RESPONSE IN INDUCTION STUDIES | No dispute reported | 06/30/2026 | 737067813 |
| Principal investigator 1 | AbbVie Inc. | $1,471.04 | 01/03/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-234 | No dispute reported | 06/30/2026 | 721144511 |
| Principal investigator 1 | AbbVie Inc. | $1,256.84 | 01/03/2020 | Non-covered Recipient Entity ATLANTA GASTROENTEROLOGY SPECIALISTS PC | M14-234 | No dispute reported | 06/30/2026 | 721144513 |